Cacna1C Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
CACNA1C encodes the alpha-1C subunit of the L-type voltage-gated calcium channel (Cav1.2), one of the most important calcium channels in [neurons](/entities/neurons) and cardiac myocytes. This channel plays critical roles in synaptic plasticity, gene transcription, and cellular excitability.
Function
Cav1.2 is an L-type voltage-gated calcium channel with several key characteristics:
Channel Type: L-type calcium channel (Cav1.2)
Primary Structure: Alpha-1 subunit with 4 repeat domains, each containing 6 transmembrane segments
Biophysical Properties: High voltage activation, slow inactivation, dihydropyridine-sensitive
Synaptic Plasticity: Couples synaptic activity to gene transcription via Ca2+-dependent signaling
Dendritic Spine Function: Regulates calcium influx in [dendritic spines](/cell-types/dendritic-spines) during [LTP](/mechanisms/long-term-potentiation) and LTD
Transcriptional Regulation: Activates CREB and other transcription factors
neuronal Development: Critical for dendritic growth and synapse formation
Disease Associations
Timothy Syndrome (TS)
Causative gene for Timothy syndrome, a multisystem disorder
Gain-of-function missense mutations (e.g., G406R) cause prolonged channel opening
Associated with cardiac arrhythmias, autism, seizures
Psychiatric Disorders
Genome-wide significant association with bipolar disorder, schizophrenia, and major depressive disorder
Risk SNPs in intronic regions affect gene expression and splicing
May affect neuronal calcium signaling and synaptic plasticity
Alzheimer's Disease
Altered Cav1.2 function affects calcium homeostasis in neurons
Involved in [amyloid-beta](/proteins/amyloid-beta)-induced synaptic dysfunction
Therapeutic target for calcium dysregulation in AD
Parkinson's Disease
Cav1.2 channels regulate dopaminergic neuron function
L-type channel blockers may protect dopaminergic neurons
Altered expression in PD brain regions
Expression
Brain: High expression in [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, cerebellum
Heart: Cardiac muscle (ventricles, atria)
Other Tissues: Smooth muscle, endocrine cells, fibroblasts
Clinical Trials: L-type channel blockers being investigated for neuroprotection in AD and PD
Key Publications
Splawski I, et al. (2004). Ca(V)1.2 calcium channel dysfunction causes cardiac and neurological disease. Nat Med.
Bialer M, et al. (2019). CACNA1C in neuropsychiatric disorders. Nat Rev Neurosci.
Muller HK, et al. (2020). L-type calcium channels in Alzheimer's disease. Mol Neurobiol.
Background
The study of Cacna1C Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Molecular Mechanisms
Channel Structure
Cav1.2 channels are composed of:
α1C subunit (CACNA1C): Forms the calcium-permeable pore
β subunits (β1-β4): Modulate trafficking and gating
α2δ subunits (α2δ1-4): Assist in channel assembly
γ subunits: Tissue-specific modulators
Gating Properties
Activation threshold: ∼-40 mV
Activation kinetics: Relatively slow compared to other VGCCs
Inactivation: Both voltage-dependent and calcium-dependent (CDI)
Recovery: Slow recovery from inactivation
Calcium-Dependent Inactivation (CDI)
Cav1.2 channels undergo CDI, a unique feature:
Calcium influx through the channel activates calmodulin
Calmodulin binds to the C-terminal tail
This triggers channel closure even during continued depolarization
Protein kinase CK2 and CaMKII modulate CDI strength
Phosphorylation
PKA phosphorylation of Cav1.2:
Increases channel open probability
Enhances L-type current amplitude
Critical for β-adrenergic regulation of cardiac function
Dysregulation linked to neuropsychiatric disorders
Therapeutic Targeting
Clinical Applications
CNS Drug Development
Isradipine: Under investigation for PD neuroprotection